These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 38545425)

  • 21. Evaluating Surgical Outcomes Between Estrogen Receptor Positive Invasive Lobular and Invasive Ductal Carcinoma of the Breast-A Propensity Matched Analysis.
    O'Connor DJ; Davey MG; McFeetors C; McLaughlin RP; Sweeney KJ; Barry MK; Malone CM; Wahab SAE; Lowery AJ; Kerin MJ
    Clin Breast Cancer; 2024 Dec; 24(8):e655-e662. PubMed ID: 39127596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathological Features and Outcomes Comparing Patients With Invasive Ductal and Lobular Breast Cancer.
    Oesterreich S; Nasrazadani A; Zou J; Carleton N; Onger T; Wright MD; Li Y; Demanelis K; Ramaswamy B; Tseng G; Lee AV; Williams N; Kruse M
    J Natl Cancer Inst; 2022 Nov; 114(11):1511-1522. PubMed ID: 36239760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Overall Survival Between Invasive Lobular Breast Carcinoma and Invasive Ductal Breast Carcinoma: A Propensity Score Matching Study Based on SEER Database.
    Yang C; Lei C; Zhang Y; Zhang J; Ji F; Pan W; Zhang L; Gao H; Yang M; Li J; Wang K
    Front Oncol; 2020; 10():590643. PubMed ID: 33415073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant chemotherapy in patients with invasive lobular carcinoma and use of the 21-gene recurrence score: A National Cancer Database analysis.
    Weiser R; Polychronopoulou E; Hatch SS; Haque W; Ghani HA; He J; Kuo YF; Gradishar WJ; Klimberg VS
    Cancer; 2022 May; 128(9):1738-1747. PubMed ID: 35137951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Comparison of the Clinicopathological Features, Metastasis Sites and Survival Outcomes of Invasive Lobular, Invasive Ductal and Mixed Invasive Ductal and Lobular Breast Carcinoma.
    Duraker N; Hot S; Akan A; Nayır PÖ
    Eur J Breast Health; 2020 Jan; 16(1):22-31. PubMed ID: 31912010
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Invasive lobular carcinoma: clinicopathological features and subtypes.
    Danzinger S; Hielscher N; Izsó M; Metzler J; Trinkl C; Pfeifer C; Tendl-Schulz K; Singer CF
    J Int Med Res; 2021 Jun; 49(6):3000605211017039. PubMed ID: 34187216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metastatic profiles and survival differences between infiltrating ductal carcinoma and infiltrating lobular carcinoma in invasive breast cancer.
    Cavaller L; Goupille C; Arbion F; Vilde A; Body G; Ouldamer L
    J Gynecol Obstet Hum Reprod; 2024 Apr; 53(4):102740. PubMed ID: 38311000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Survival Differences Between T1-2 Invasive Lobular Breast Cancer and Corresponding Ductal Carcinoma After Breast-Conserving Surgery: A Propensity-Scored Matched Longitudinal Cohort Study.
    Wang K; Zhu GQ; Shi Y; Li ZY; Zhang X; Li HY
    Clin Breast Cancer; 2019 Feb; 19(1):e101-e115. PubMed ID: 30502219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lymph-node metastases in invasive lobular carcinoma are different from those in ductal carcinoma of the breast.
    Fernández B; Paish EC; Green AR; Lee AH; Macmillan RD; Ellis IO; Rakha EA
    J Clin Pathol; 2011 Nov; 64(11):995-1000. PubMed ID: 21712309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Axillary lymph node and non-sentinel lymph node metastasis among the ACOSOG Z0011 eligible breast cancer patients with invasive ductal, invasive lobular, or other histological special types: a multi-institutional retrospective analysis.
    Gao W; Zeng Y; Fei X; Chen X; Shen K
    Breast Cancer Res Treat; 2020 Nov; 184(1):193-202. PubMed ID: 32740809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of a nuclear grading system for resected stage I-IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial.
    Tsuda H; Kurosumi M; Akiyama F; Ohno S; Saji S; Masuda N; Shimomura A; Sato N; Takao S; Ohsumi S; Tokuda Y; Inaji H; Watanabe T
    Breast Cancer; 2022 Jul; 29(4):720-729. PubMed ID: 35435571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lobular Histology Does Not Predict the Need for Axillary Dissection Among ACOSOG Z0011-Eligible Breast Cancers.
    Mamtani A; Zabor EC; Stempel M; Morrow M
    Ann Surg Oncol; 2019 Oct; 26(10):3269-3274. PubMed ID: 31342363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The 21-gene recurrence score in early non-ductal breast cancer: a National Cancer Database analysis.
    Makower D; Qin J; Lin J; Xue X; Sparano JA
    NPJ Breast Cancer; 2022 Jan; 8(1):4. PubMed ID: 35027533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study.
    Dalenc F; Lusque A; De La Motte Rouge T; Pistilli B; Brain E; Pasquier D; Debled M; Thery JC; Gonçalves A; Desmoulins I; Levy C; Uwer L; Ferrero JM; Eymard JC; Mouret-Reynier MA; Patsouris A; Frenel JS; Petit T; Chevrot M; Bachelot T; Guiu S
    Eur J Cancer; 2022 Mar; 164():70-79. PubMed ID: 35176614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical Trials.
    Pérez-Garcia J; Cortés J; Metzger Filho O
    Oncologist; 2019 Aug; 24(8):1041-1047. PubMed ID: 30578311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival Outcomes in Invasive Lobular Carcinoma Compared to Oestrogen Receptor-Positive Invasive Ductal Carcinoma.
    Timbres J; Moss C; Mera A; Haire A; Gillett C; Van Hemelrijck M; Sawyer E
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34207042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
    Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
    Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
    Rastogi P; O'Shaughnessy J; Martin M; Boyle F; Cortes J; Rugo HS; Goetz MP; Hamilton EP; Huang CS; Senkus E; Tryakin A; Cicin I; Testa L; Neven P; Huober J; Shao Z; Wei R; André V; Munoz M; San Antonio B; Shahir A; Harbeck N; Johnston S
    J Clin Oncol; 2024 Mar; 42(9):987-993. PubMed ID: 38194616
    [No Abstract]   [Full Text] [Related]  

  • 39. Invasive lobular carcinoma of the breast: A special histological type compared with invasive ductal carcinoma.
    Chen Z; Yang J; Li S; Lv M; Shen Y; Wang B; Li P; Yi M; Zhao X; Zhang L; Wang L; Yang J
    PLoS One; 2017; 12(9):e0182397. PubMed ID: 28863134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights.
    Da Ros L; Moretti A; Querzoli P; Pedriali M; Lupini L; Bassi C; Carcoforo P; Negrini M; Frassoldati A
    Clin Breast Cancer; 2018 Oct; 18(5):e1133-e1139. PubMed ID: 29759595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.